Avience Biomedicals IPO Subscription Status: Final Allotment Set for June 23!

The Avience Biomedicals IPO has recently opened for subscription, currently witnessing a subscription rate of 0x overall as of Day 1, updated on June 15, 2026. This indicates that there is minimal participation from the retail investor segment at this early stage. The IPO window is set to remain open from June 18 to June 22, 2026, allowing investors several days to assess their interest in the offering. The shares are scheduled to be listed on the stock exchanges on June 25, 2026, marking a significant milestone for the company if demand increases in the coming days.

The undersubscribed status of the Avience Biomedicals IPO presents a unique opportunity for retail investors, as the lower subscription rate suggests a higher probability for allotment. This could attract cautious investors looking for favorable odds in a market that often sees high competition for shares. If retail participation ramps up as the subscription period progresses, it may help bolster the overall demand and improve interest in biotech-related investments in the Indian markets.

For Indian investors, the current grey market sentiment around the Avience Biomedicals IPO remains muted due to the lack of subscription activity. However, should investor sentiment shift positively in the coming days, it may lead to a more robust discussion in the market. The eventual listing will be instrumental in gauging the market’s appetite for biotech IPOs, especially in light of evolving healthcare demands and innovation in the sector. A successful listing could pave the way for future biotech ventures in the Indian IPO landscape and provide strategic insights for investors navigating this niche market.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)